This Insider Has Just Sold Shares In Pfizer Inc. (NYSE:PFE)

Some Pfizer Inc. (NYSE:PFE) shareholders may be a little concerned to see that insider Mikael Dohlsten recently sold a substantial US$3.2m worth of stock at a price of US$49.32 per share. That's a big disposal, and it decreased their holding size by 16%, which is notable but not too bad.

View our latest analysis for Pfizer

The Last 12 Months Of Insider Transactions At Pfizer

Over the last year, we can see that the biggest insider sale was by the , John Young, for US$7.5m worth of shares, at about US$50.16 per share. So we know that an insider sold shares at around the present share price of US$49.92. While we don't usually like to see insider selling, it's more concerning if the sales take place at a lower price. In this case, the big sale took place at around the current price, so it's not too bad (but it's still not a positive).

In the last year Pfizer insiders didn't buy any company stock. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

If you like to buy stocks that insiders are buying, rather than selling, then you might just love this free list of companies. (Hint: insiders have been buying them).

Insider Ownership of Pfizer

For a common shareholder, it is worth checking how many shares are held by company insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. It's great to see that Pfizer insiders own 0.04% of the company, worth about US$106m. I like to see this level of insider ownership, because it increases the chances that management are thinking about the best interests of shareholders.

What Might The Insider Transactions At Pfizer Tell Us?

Insiders haven't bought Pfizer stock in the last three months, but there was some selling. Looking to the last twelve months, our data doesn't show any insider buying. But since Pfizer is profitable and growing, we're not too worried by this. It is good to see high insider ownership, but the insider selling leaves us cautious. While we like knowing what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. Case in point: We've spotted 2 warning signs for Pfizer you should be aware of, and 1 of these can't be ignored.

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.